IDSA guideline strongly recommends an age-appropriate 2025-2026 influenza vaccine for all immunocompromised individuals aged ≥6 months; direct evidence showed vaccination reduced influenza-associated hospitalisation by 32%, with no increased Guillain-Barré risk detected.
Guideline
Goepfert et al. IDSA 2025 Guideline on the Use of Vaccines for the Prevention of Seasonal Influenza Infections in Immunocompromised Patients